On May 27, 2025, Canaccord Genuity analyst Susan Anderson initiated coverage on Niagen Bioscience (NAGE, Financial) with a 'Buy' rating. This announcement marks the beginning of coverage for NAGE by Canaccord Genuity.
The firm has set a price target of $13.00 USD for NAGE, providing investors with a new benchmark for assessing the potential value of Niagen Bioscience stock.
As of the initiation date, there is no prior price target or rating for NAGE from Canaccord Genuity, making this the initial evaluation for the company by the analyst.
Investors and industry observers will be closely watching Niagen Bioscience (NAGE, Financial) following this coverage initiation, looking to see how the stock responds to the 'Buy' rating and the new price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Niagen Bioscience Inc (NAGE, Financial) is $9.03 with a high estimate of $12.00 and a low estimate of $8.00. The average target implies an downside of 8.65% from the current price of $9.88. More detailed estimate data can be found on the Niagen Bioscience Inc (NAGE) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Niagen Bioscience Inc's (NAGE, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Niagen Bioscience Inc (NAGE, Financial) in one year is $2.71, suggesting a downside of 72.57% from the current price of $9.88. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Niagen Bioscience Inc (NAGE) Summary page.
